You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 59 No. 3, March 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (57)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Nutritional and Metabolic Disorders
 •Metabolism
 •Depression
 •Obsessive-Compulsive Disorder
 •Psychopharmacology
 •Alert me on articles by topic

Differential Cerebral Metabolic Changes With Paroxetine Treatment of Obsessive-Compulsive Disorder vs Major Depression

Sanjaya Saxena, MD; Arthur L. Brody, MD; Matthew L. Ho, BS; Shervin Alborzian, BS; Karron M. Maidment, RN; Narineh Zohrabi, BS; Mai K. Ho, BS; Sung-Cheng Huang, PhD; Hsiao-Ming Wu, PhD; Lewis R. Baxter, Jr, MD

Arch Gen Psychiatry. 2002;59:250-261.

Background  Serotonin reuptake inhibitors (SRIs) effectively treat both major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). We compared and contrasted the functional neuroanatomical effects of SRIs in OCD and MDD as these 2 disorders occurred separately and concurrently by measuring pretreatment to posttreatment cerebral glucose metabolic changes in OCD vs MDD vs concurrent OCD + MDD.

Methods  We obtained [18F]fluorodeoxyglucose positron emission tomography (PET) brain scans on 25 subjects with OCD, 25 with MDD, and 16 with concurrent OCD + MDD before and after 8 to 12 weeks of treatment with paroxetine hydrochloride. Controls (n = 16) were scanned 10 to 12 weeks apart without treatment. Treatment response was defined as a more than 25% decline in OCD symptom severity, a more than 50% decline in MDD severity, and "much improved" clinical global impression.

Results  Although all patient groups received the same paroxetine dose for the same duration, regional metabolic changes differed significantly among diagnostic groups. Subjects with OCD alone showed significant metabolic decreases in the right caudate nucleus, right ventrolateral prefrontal cortex (VLPFC), bilateral orbitofrontal cortex, and thalamus that were not seen in any other group. Both the MDD and concurrent OCD + MDD groups showed metabolic decreases in the left VLPFC and increases in the right striatum. Treatment response was associated with a decrease in striatal metabolism in nondepressed OCD patients but with an increase in striatal activity in patients with OCD + MDD.

Conclusions  Brain metabolic responses to SRIs are both disorder-specific and response-specific. They vary according to the underlying pathophysiology of the patient and the degree of symptomatic improvement.


From the Departments of Psychiatry and Biobehavioral Sciences (Drs Saxena, Brody, and Baxter, Messrs M. L. Ho and Alborzian, and Mss Maidment, Zohrabi, and M. K. Ho) and Molecular and Medical Pharmacology (Drs Huang, Wu, and Baxter), School of Medicine, University of California, Los Angeles; and the Department of Psychiatry and Behavioral Neurobiology, School of Medicine, University of Alabama, Birmingham (Dr Baxter).



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Identifying Functional Neuroimaging Biomarkers of Bipolar Disorder: Toward DSM-V
Phillips and Vieta
Schizophr Bull 2007;33:893-904.
ABSTRACT | FULL TEXT  

Response-Dependent Differences in Regional Cerebral Blood Flow Changes with Citalopram in Treatment of Major Depression
Joe et al.
JNM 2006;47:1319-1325.
ABSTRACT | FULL TEXT  

Metabolic Imaging of Anterior Capsular Stimulation in Refractory Obsessive-Compulsive Disorder: A Key Role for the Subgenual Anterior Cingulate and Ventral Striatum
Van Laere et al.
JNM 2006;47:740-747.
ABSTRACT | FULL TEXT  

Catechol-O-Methyltransferase val158met Genotype Affects Processing of Emotional Stimuli in the Amygdala and Prefrontal Cortex
Smolka et al.
J. Neurosci. 2005;25:836-842.
ABSTRACT | FULL TEXT  

Subtype-Specific Alterations of {gamma}-Aminobutyric Acid and Glutamate in Patients With Major Depression
Sanacora et al.
Arch Gen Psychiatry 2004;61:705-713.
ABSTRACT | FULL TEXT  

Cerebral Glucose Metabolism in Obsessive-Compulsive Hoarding
Saxena et al.
Am. J. Psychiatry 2004;161:1038-1048.
ABSTRACT | FULL TEXT  

Distinct Neural Correlates of Washing, Checking, and Hoarding Symptom Dimensions in Obsessive-compulsive Disorder
Mataix-Cols et al.
Arch Gen Psychiatry 2004;61:564-576.
ABSTRACT | FULL TEXT  

Insulin Resistance, Affective Disorders, and Alzheimer's Disease: Review and Hypothesis
Rasgon and Jarvik
J. Gerontol. A Biol. Sci. Med. Sci. 2004;59:M178-183.
ABSTRACT | FULL TEXT  

Differential Brain Metabolic Predictors of Response to Paroxetine in Obsessive-Compulsive Disorder Versus Major Depression
Saxena et al.
Am. J. Psychiatry 2003;160:522-532.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.